Last reviewed · How we verify
ARNI
At a glance
| Generic name | ARNI |
|---|---|
| Also known as | Entresto |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap? (PHASE4)
- The STOP-MED CTRCD Trial (PHASE4)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
- Baroreflex Activation Therapy for Heart Failure (NA)
- A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients (PHASE3)
- Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy (PHASE2,PHASE3)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
- Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARNI CI brief — competitive landscape report
- ARNI updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI